论文部分内容阅读
白细胞介素 - 2 2 (IL- 2 2 )起初系在鼠 T淋巴细胞中经 IL- 9诱生而获得的 ,并因此被命名为 IL- TIF(IL-10 - related- derived inducible factor) ;鉴于其与 IL- 10的结构相似性 ,其受体是一个已建立的细胞因子受体家族的新成员 ,以及其在白细胞内的产物和作用的确认 ,2 0 0 0年由 Xie等提出将其重命名为一个新的人类细胞因子白细胞介素 - 2 2 (IL- 2 2 )。实验证明 IL- 2 2上调肝细胞急性期产物 ,参与炎症反应。借助 IL- 9或 CD3抗体和刀豆蛋白 A的激活 ,T细胞、肥大细胞、胸腺和脑均可表达 IL- 2 2 ,表明这个因子在免疫系统内外可能显示多效的活性。在抗体免疫应答中 ,其对来自 TH2 T细胞的 IL- 4产物有适当的抑制作用 ,对于哮喘有潜在的治疗作用。在信号转导途径中 ,IL- 2 2能介导 STAT1、STAT3和 STAT5的激活
Interleukin-2 2 (IL-2 2) was originally obtained by IL-9 induction in murine T lymphocytes and was therefore named IL-10-related-derived inducible factor; In view of its structural similarity to IL-10, its receptor is a new member of an established family of cytokine receptors and its confirmation of the product and effect in leukocytes. Proposed in 2000 by Xie et al. It was renamed as a new human cytokine interleukin-2 (IL-2 2). Experiments show that IL-2 2 up-regulated hepatocytes in the acute phase of the product, involved in the inflammatory response. With the activation of IL-9 or CD3 antibodies and concanavalin A, IL-2 can be expressed in T cells, mast cells, thymus and brain, indicating that this factor may show pleiotropic activity both inside and outside the immune system. In the antibody immune response, it has an appropriate inhibitory effect on IL-4 products from TH2 T cells and has a potential therapeutic effect on asthma. In the signal transduction pathway, IL-2 2 can mediate the activation of STAT1, STAT3 and STAT5